A Phase III Randomized Placebo-Controlled Double-Blind Clinical Study of Pembrolizumab Mk-3475 With or Without Lenvatinib E7080/Mk-7902 to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib as 1L Intervention in a PD-L1 Selected Population of Participants with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma R/M HNSCC LEAP-010

Brief Summary

Type:
Head and Neck Cancers

Study Type:
Treatment

Phase:
III

ClinicalTrials.gov Identifier:
NCT04199104

Study #:
STUDY00145045

Start Date:
Sep 16, 2020

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT04199104

View Complete Trial Details & Eligibility at ClinicalTrials.gov